Publications by authors named "Eduardo Forleo-Neto"

Claim this Profile
E
Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial.
Flonza Isa, Ana M Gonzalez Ortiz, Jonathan Meyer, Jennifer D Hamilton, Benjamin A Olenchock, Eduardo Forleo-Neto

Lancet Infect Dis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monoclonal antibodies against the spike protein alter the endogenous humoral response to SARS-CoV-2 vaccination and infection.
Christopher D Petro, Andrea T Hooper, Avery Peace, Kusha Mohammadi, Will Eagan, Eduardo Forleo-Neto

Sci Transl Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nasopharyngeal Viral Load Is the Major Driver of Incident Antibody Immune Response to SARS-CoV-2 Infection.
Meng Xu, Meagan P O'Brien, Andrea T Hooper, Eduardo Forleo-Neto, Flonza Isa

Open Forum Infect Dis· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial.
Maja Di Rocco, Eduardo Forleo-Neto, Robert J Pignolo, Richard Keen, Philippe Orcel

Nat Med· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Prospective Study of Key Correlates for Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2.
Elizabeth R Brown, Meagan P O'Brien, Brian Snow, Flonza Isa, Eduardo Forleo-Neto

Open Forum Infect Dis· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration.
Dean Follmann, Meagan P O'Brien, Jonathan Fintzi, Michael P Fay, David Montefiori, Eduardo Forleo-Neto

Nat Commun· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double-Blind Trial.
Selin Somersan-Karakaya, Eleftherios Mylonakis, Jenni Mou, Ernesto Oviedo-Orta, Meagan P O'Brien, Eduardo Forleo-Neto

Open Forum Infect Dis· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19.
Selin Somersan-Karakaya, Eleftherios Mylonakis, Vidya P Menon, Jason C Wells, Shazia Ali, Eduardo Forleo-Neto

J Infect Dis· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.
Gary A Herman, Meagan P O'Brien, Eduardo Forleo-Neto, Neena Sarkar, Flonza Isa

Lancet Infect Dis· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19.
Flonza Isa, Eduardo Forleo-Neto, Jonathan Meyer, Wenjun Zheng, Scott Rasmussen

Int J Infect Dis· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial.
Cynthia Portal-Celhay, Eduardo Forleo-Neto, Will Eagan, Bret J Musser, John D Davis

JAMA Netw Open· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
Meagan P O'Brien, Eduardo Forleo-Neto, Neena Sarkar, Flonza Isa, Peijie Hou

JAMA· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants.
Eric A F Simões, Eduardo Forleo-Neto, Gregory P Geba, Mohamed Kamal, Feng Yang

Clin Infect Dis· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
Meagan P O'Brien, Eduardo Forleo-Neto, Neena Sarkar, Flonza Isa, Peijie Hou

medRxiv· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.
Meagan P O'Brien, Eduardo Forleo-Neto, Bret J Musser, Flonza Isa, Kuo-Chen Chan

N Engl J Med· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous REGEN-COV Antibody Combination for Covid-19 Prevention.
Meagan P O'Brien, Eduardo Forleo-Neto, Bret J Musser, Flonza Isa, Kuo-Chen Chan

medRxiv· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti-Activin A): Results From a First-in-Human Phase 1 Study.
Frédéric Vanhoutte, Su Liang, Marcella Ruddy, An Zhao, Tiera Drewery, Eduardo Forleo-Neto

J Clin Pharmacol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study.
Stephan Bart, Kevin Cannon, Darrell Herrington, Richard Mills, Eduardo Forleo-Neto

Hum Vaccin Immunother· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Assessment of a Single Dose and a 2-dose Vaccination Series of a Quadrivalent Meningococcal CRM-conjugate Vaccine (MenACWY-CRM) in Children 2-10 Years of Age.
William Johnston, Brandon Essink, Judith Kirstein, Eduardo Forleo-Neto, Sandra Percell

Pediatr Infect Dis J· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-inferiority of mammalian cell-derived quadrivalent subunit influenza virus vaccines compared to trivalent subunit influenza virus vaccines in healthy children: a phase III randomized, multicenter, double-blind clinical trial.
Robyn Hartvickson, Marilou Cruz, John Ervin, Donald Brandon, Eduardo Forleo-Neto

Int J Infect Dis· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of concomitant administration of a combined hepatitis A/B vaccine and a quadrivalent meningococcal conjugate vaccine in healthy adults.
Martin Alberer, Gerd Burchard, Tomas Jelinek, Emil C Reisinger, Seetha Meyer, Eduardo Forleo-Neto

J Travel Med· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.
Martin Alberer, Gerd Burchard, Tomas Jelinek, Emil Reisinger, Jiri Beran, Eduardo Forleo-Neto

J Travel Med· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dissecting the immune response to MF59-adjuvanted and nonadjuvanted seasonal influenza vaccines in children less than three years of age.
Luisanna Zedda, Eduardo Forleo-Neto, André Vertruyen, Marc Raes, Arnaud Marchant

Pediatr Infect Dis J· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children.
Terry Nolan, Lulu Bravo, Ana Ceballos, Essack Mitha, Glenda Gray, Eduardo Forleo-Neto

Vaccine· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects.
Sharon E Frey, Mari Rose Aplasca-De Los Reyes, Humberto Reynales, Nancy Nazaire Bermal, Uwe Nicolay, Eduardo Forleo-Neto

Vaccine· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis